- Open Access
Distinguishing neurocognitive deficits in adult patients with NP-C from early onset Alzheimer’s dementia
Orphanet Journal of Rare Diseasesvolume 13, Article number: 91 (2018)
Niemann-Pick disease type C (NP-C) is a rare, progressive neurodegenerative disease caused by mutations in the NPC1 or the NPC2 gene. Neurocognitive deficits are common in NP-C, particularly in patients with the adolescent/adult-onset form. As a disease-specific therapy is available, it is important to distinguish clinically between the cognitive profiles in NP-C and primary dementia (e.g., early Alzheimer’s disease; eAD).
In a prospective observational study, we directly compared the neurocognitive profiles of patients with confirmed NP-C (n = 7) and eAD (n = 15). All patients underwent neurocognitive assessment using dementia screening tests (mini-mental status examination [MMSE] and frontal assessment battery [FAB]) and an extensive battery of tests assessing verbal memory, visuoconstructive abilities, visual memory, executive functions and verbal fluency.
Overall cognitive impairment (MMSE) was significantly greater in eAD vs. NP-C (p = 0.010). The frequency of patients classified as cognitively ‘impaired’ was also significantly greater in eAD vs. NP-C (p = 0.025). Patients with NP-C showed relatively preserved verbal memory, but frequent impairment in visual memory, visuoconstruction, executive functions and in particular, verbal fluency. In the eAD group, a wider profile of more frequent and more severe neurocognitive deficits was seen, primarily featuring severe verbal and visual memory deficits along with major executive impairment. Delayed verbal memory recall was a particularly strong distinguishing factor between the two groups.
A combination of detailed yet easy-to-apply neurocognitive tests assessing verbal memory, executive functions and verbal fluency may help distinguish NP-C cases from those with primary dementia due to eAD.
Niemann-Pick disease type C (NP-C) is a rare, progressive neurodegenerative disease caused by mutations in the NPC1 or the NPC2 gene, which lead to impaired cholesterol metabolism [1, 2]. Neurocognitive and neuropsychiatric deficits are commonly reported in patients NP-C, particularly among patients with the adolescent/adult-onset form [1, 3,4,5]. Early-onset cognitive decline (EOCD) is characterised by presentation of cognitive impairment before the age of 65 years, and clinical diagnoses of EOCD are increasingly being reported. Most cases are related to early Alzheimer’s disease (eAD). However, compared to dementia in patients aged > 65 years, there is a much wider range of differential diagnoses, including underlying inherited neurodegenerative aetiologies such as NP-C.
NP-C shares a number of clinical and neuropathological features in common with AD and other dementias, including eAD, frontotemporal dementia (FTD), and Lewy body dementia [6,7,8,9,10]. Patients with EOCD and eAD have therefore been suggested as a potential clinical niche for the identification of new, as yet undetected cases of NP-C . In particular, patients with dementia-plus syndromes featuring concomitant psychiatric symptoms, movement disorders such as degenerative ataxia and/or vertical supranuclear saccade palsy (VSSP) are also considered to have an increased likelihood of having NP-C [11,12,13].
Although the burden of clinical symptoms of adult NP-C patients impacts on activities of daily living, cerebral magnetic resonance imaging (MRI) findings are usually normal or show non-specific minor cerebral atrophy [2, 5]. Thus, cognitive deterioration among patients with adolescent/adult-onset NP-C can easily be mistaken for primary psychiatric disorders or other neurodegenerative dementias [12,13,14]. It is therefore important to be able to distinguish at the initial clinical level between the cognitive profile of patients with NP-C and those with common dementia subtypes such as eAD. However, there are few published studies on valid neurocognitive tests that could be used to distinguish adult NP-C patients from those with other neurodegenerative dementia aetiologies .
A wide range of neurocognitive symptoms are encountered among NP-C patients, but published data on the specific neurocognitive profile of NP-C are based on studies adopting a range of methodologies, resulting in inconsistent or incomplete findings [12, 16,17,18,19]. Early signs of cognitive impairment have been reported to comprise reduced executive function, processing speed, and verbal memory due to frontal-subcortical neural dysfunction [3, 17, 19]. Continued disease progression leads to further general cognitive decline, progressive deterioration in abilities to perform daily tasks, highly diminished memory, and behavioural impairment [5, 17, 20, 21].
Based on findings from a pilot study in 10 patients with NP-C, Klarner et al.  reported impairments in fine motor skills, language, attention, working memory, and visuospatial functions. A number of deficits similar to those seen in eAD were observed, including verbal episodic memory impairment. Appropriate neurocognitive tests incorporating disease staging were recommended to detect NP-C: the Trail Making tests (TMT) A & B and verbal fluency tests were judged as most useful in patients with mild disease, and The Mini-Mental Status Examination (MMSE), Corsi Block-tapping, Find Similarities, and Clock Drawing Tests were considered more appropriate in patients with more advanced disease. Other, separate studies have reported frontal impairments and decreases in executive functions and attention [5, 16]. A systematic literature review of case reports based on 23 separate patients has also reported executive dysfunction as the most frequent cognitive deficit in adult NP-C , possibly due to neuropathology in cerebellar regions and deep grey matter nuclei (e.g., the thalamus and striatum). Overall, the current literature points towards attentional and executive dysfunctions as the hallmark of neurocognitive impairment in patients with NP-C. However, it remains unclear whether the previously recommended tests assessing these cognitive domains could help distinguish NP-C patients from other dementia subtypes such as eAD.
The recognition of NP-C as early as possible in the disease course is important as a current treatment (miglustat) is available in Europe and many other countries that may help stabilise the progression of neurological and neurocognitive symptoms. Intrathecal hydroxypropyl-beta-cyclodextrin is a promising future alternative treatment that is currently undergoing clinical trials. Encouraging data with this agent were reported by Ory et al. in 2017, and further studies are ongoing [14, 16, 22,23,24,25].
The advent of biochemical laboratory markers and the increasing availability of next-generation gene sequencing methods are major advances for the identification of new cases of NP-C. However, these methods are only applied in patients or patient groups considered at high risk of NP-C. Clinical methods of defining the level of risk or suspicion of NP-C are necessary to direct such further diagnostic investigations. The characterization and delineation of the neurocognitive profile of NP-C may help clinicians to achieve earlier diagnoses, particularly when combined with approaches that help distinguish potential cases from another primary degenerative disease such as eAD.
In this study, we used a detailed neurocognitive test battery to assess whether there is a recognizable, specific profile of deficits in adult patients with genetically proven NP-C. We were particularly interested in whether neurocognitive tests from attentional and executive domains identified by previous studies as useful in the detection of NP-C (e.g., TMT-A and B, verbal fluency tests) were able to differentiate NP-C from eAD. Importantly and in contrast to previous studies , the neurocognitive test battery used here was geared towards the typical age span of patients with adult NP-C and eAD instead of senile dementia, in which ceiling effects must be expected. Thus, we conducted the first direct comparison of the observed NP-C neurocognitive profile with a reference group of adults with confirmed eAD, the most frequent aetiology of EOCD.
This was a prospective observational cohort study including consecutive patients encountered at the Memory Disorder Unit at the Department of Neurology, University Hospital Münster, Germany between 2012 and 2016. All participants had confirmed pathogenic NPC1 genotypes.
Included patients underwent neurological and psychiatric examination by a physician trained in the assessment of patients suffering from dementia. Lumbar puncture, electroencephalography, event-related potentials (P300), 3.0 Tesla brain MRI, and comprehensive neurocognitive testing were also performed. Within the eAD group, all patients were classified as having probable eAD according to McKhann criteria , with at least intermediate pathophysiological evidence of AD based on cerebrospinal fluid biomarker profile and MRI brain atrophy pattern. All patients underwent follow-up visits for ≥12 months. Functional disability was evaluated in NP-C patients using a well-established and validated disease-specific disability scale for NP-C , which assesses six key domains (ambulation, manipulation, language, swallowing, ocular movements, and epilepsy) on a composite scale with scores ranging from 0 (best) to 24 (worst).
Subjects with a history of neurological disorders other than eAD or NP-C such as other dementia subtypes, other neurodegenerative disorders (e.g., Huntington’s disease, multiple system atrophy, motor neuron disease), stroke, hydrocephalus, epilepsy, brain tumour, traumatic brain injury, major psychiatric illness not related to dementia (e.g., drug or alcohol abuse), and other systemic diseases known to interfere with cognitive function were excluded.
Demographic data and clinical parameters were collected for all patients. An extensive battery of neurocognitive tests was applied, which assessed all major cognitive domains. The test battery included: the German equivalent of the Rey Auditory Verbal Learning Test (RAVLT)  for verbal span, verbal learning efficiency, verbal short-term retrieval, verbal long-term retrieval, and verbal recognition; the Rey Complex Figure Test and Recognition Trial (RCFT)  for visuoconstructive abilities and visual short-term retrieval; TMT-A and -B for processing speed, and set-shifting speed, respectively ; the Regensburger verbal fluency test (RWT)  for lexical and semantic word fluency; and the forwards and backwards digit span tests from the Wechsler Memory Scale (WMS)  for attention and working memory capacity. Among these neurocognitive parameters, lower raw scores indicate better performance on the TMT-A, TMT-B, RCFT time to copy, the RAVLT5–6, and RAVLT5–7 scores. Higher raw scores signify better performance for all other parameters.
Overall cognitive function was screened using the MMSE , where higher scores represent less impairment. Frontal-executive impairment was screened using the Frontal Assessment Battery (FAB), where higher scores also indicate less impairment .
Between-group differences were evaluated using the Welch t-test for normally distributed data, and the non-parametric Mann-Whitney test for non-normally distributed data. Raw scores from all neurocognitive tests were transformed into normative percentile ranks stratified by age, gender and education, where cognitive ‘impairment’ was defined when patients scored below the 10th percentile rank (PR) of the respective normative sample detailed in the professional manuals for each test. The proportions of patients categorized as ‘impaired’ based on their neurocognitive profiles were compared between the NP-C and eAD groups using the Chi-square test. For all between-group comparisons, statistical significance was concluded at the p < 0.05 level.
Cohen’s d effect-sizes for between-group differences, taking into account the within-group variance and homogeneity of scores, were derived for each test parameter. Based on this analysis, receiver operating characteristics (ROC) curves were used to calculate the sensitivity and specificity of the parameter with the largest effect-size for differential diagnosis between NP-C and eAD, and in test parameters previously suggested to be useful in detecting mild NP-C .
A total of nine patients with NP-C were selected for inclusion in the study, all of whom had confirmed diagnoses based on molecular genetic testing. Two NP-C patients who were initially selected for the study were excluded from the data analysis because they were not testable due to the severity of their motor dysfunction. Individual patient demographics, disease characteristics, biochemical variables and disability scores of the seven included NP-C patients are presented in Table 1. All seven patients had been symptomatic (symptom duration 6–14 years) and were on ongoing miglustat treatment for a range of 3–14 months. Ataxia was the most common symptom at initial presentation (three patients), followed by cataplexy and dysarthria (in two patients each). None of the patients in this cohort showed more than mild dementia, and no patients presented with epileptic seizures or psychotic symptoms. Disability scores indicated relatively mild disease severity .
Table 2 shows a comparison of NP-C and eAD patient group characteristics. The mean ± SD age of the adult/adolescent onset NP-C patients in this cohort (34.6 ± 12.2 years) was significantly lower than that in the reference group of eAD patients (55.1 ± 3.4 years; p = 0.004). Patients in both groups had a similar level of education.
Disease biomarker levels in the eAD group confirmed that all eAD patients had notable/substantial AD pathology. Amyloid-ß and total tau levels were measured in four NP-C patients. Mean total tau concentration was significantly higher in the eAD group compared with NP-C patients (p = 0.03), and amyloid-ß levels were significantly lower among eAD patients (p < 0.01) (Table 2).
Neurocognitive test results
Dementia screening indicated significantly greater overall cognitive impairment among eAD patients compared with NP-C patients based on MMSE scores (p = 0.010). While no statistical difference in frontal-executive impairment between NP-C and eAD patients was observed based on FAB screening (p = 0.245).
The frequencies of cognitive impairment in relation to data from age-matched normative samples for both patient groups are summarised in Fig. 1. Overall, patients with NP-C showed a cognitive profile of relatively preserved verbal episodic memory (RAVLT), but visuoconstruction and visual memory (RCFT recall [visual memory] and RCFT copy scores) were frequently impaired. Deficits in attention and executive functions (i.e., processing speed [TMT-A], set-shifting [TMT-B], and RWT word fluency) were also common. In contrast, patients with eAD generally showed a wider profile of cognitive impairment. Deficits in verbal learning and memory (RAVLT), visuoconstruction and visual memory (RCFT), and executive functions (TMT and verbal fluency scores) were similarly or more frequent than in the NP-C group.
Overall, Chi-square analysis showed that impaired test parameters (i.e., those with performance scores PR < 10) were significantly more frequent in the eAD group compared with the NP-C group (p = 0.025). The largest discrepancies in the frequency of cognitive impairments between the NP-C and eAD groups were in terms of verbal memory deficits (all RAVLT parameters), which were substantially more frequently observed in eAD patients.
Mean ± SD neurocognitive test raw scores are summarised in Table 3. In the majority of neurocognitive test parameters, significantly greater average impairment was seen in eAD compared with the NP-C group. Significant between-group differences indicated greater degrees of impairment in eAD patients in most RAVLT subscales (p-values from < 0.001 to 0.018), the RCFT copy subscale (p = 0.038) and the WMS digit span backwards test (p = 0.037). Notably, the TMT-B score, which has been highlighted as a particularly suggestive test for executive dysfunction in NP-C, was also significantly more impaired in the eAD group versus the NP-C group (p = 0.017).
No other cognitive tests showed significant between-group differences. However, NP-C patients showed a marginally (albeit non-significantly) worse average performance on the RWT phonematic word fluency (letter S) test compared with eAD patients (p = 0.225).
Among all of the neurocognitive tests we applied, the greatest difference between the NP-C and eAD groups in terms of deficit frequency was in RAVLT7 (delayed verbal recall) scores. This parameter also showed the greatest between-group effect size in terms of raw scores. ROC analysis showed that this parameter discriminated well between patients with NP-C and those with eAD, with an area under the curve (AUC) of 0.981 demonstrating both high sensitivity (85.7%) and high specificity (93.3%) using a cut-off of 6/15 recalled words after 30 min. Other neurocognitive tests, including those previously suggested as effective in detecting mild NP-C, showed insufficient discriminative power (all AUC values < 0.7) (Fig. 2).
Importantly, there did not appear to be any influence of neurological deficits (e.g., speech or manipulation impairment) on patients’ performance of neurocognitive tests. Subscores for these domains on the NP-C disability scale assessments showed only slight to moderate impairements: all subscores were ≤ 3 for all patients.
This is the first study to directly compare the neurocognitive symptom profile of patients with NP-C with that seen in a ‘reference’ group of patients with deficits due to eAD – the most common primary neurodegenerative dementia syndrome before the age of 65 years. The detailed battery of neurocognitive tests applied in this study identified specific, statistically significant differences between the NP-C and eAD groups, which may aid in the differential diagnosis of patients with early cognitive impairment and further neurological deficits (i.e., dementia-plus syndrome) suggestive of possible NP-C.
NP-C and AD share a number of pathophysiological similarities such as increased levels of brain tau protein, amyloid deposition, the presence of neurofibrillary tangles, and the influence of apolipoprotein E ε4 genotype [6,7,8,9, 35]. Other neurological commonalities include basal forebrain cholinergic system alterations and chronic neuroinflammation [36,37,38]. However, there are distinct differences in the localisation of neuropathology between the two conditions. Purkinje cells in the cerebellum are the most affected neurons in NP-C, with NFTs mainly found in subcortical structures, while lesions in AD are mainly seen in the neocortical and medial temporal lobes [6, 15, 39, 40]. It therefore follows that certain clinical neurocognitive differences exist between NP-C and eAD patients [16, 17].
MRI and diffusion tensor imaging (DTI) studies in NP-C patients have suggested that cerebral atrophy in key deep grey matter regions including the hippocampus, thalamus, cerebellum, and striatum, as well as major white-matter tracts, may account for global impairments in cognitive function in NP-C [41,42,43]. More specifically, positron emission tomography (PET) studies in adult NP-C patients have indicated that frontal-lobe hypometabolism may contribute to frontal-executive deficits [44, 45].
Overall, taking patient age, gender, and education into account, eAD patients showed wider, more generalised impairments in affected cognitive domains compared with the profile seen in NP-C patients in the current study. Deficits were also more frequent and greater in magnitude in eAD on most of the neurocognitive tests that we employed. Bergeron et al. reported that in contrast to NP-C, the general cognitive profile in AD is characterized predominantly by memory dysfunction . In the current study, the key neurocognitive difference between NP-C and eAD was also observed in terms of verbal memory performance, as measured by the RAVLT. Most RAVLT subscores (excluding forgetfulness after interference) were statistically significantly more impaired in eAD patients. In particular, the RAVLT7 subscale (delayed verbal recall), an indicator of verbal memory that has been shown to correlate with hippocampal pathology [46, 47], showed the greatest effect size between the two groups. Our ROC analyses suggested that delayed verbal recall also showed good sensitivity and specificity in distinguishing between NP-C and eAD patients. Relatively preserved verbal memory has recently also been reported in a French cohort of 21 patients with mild adult NP-C .
With regard to alternative tests for verbal episodic memory, the Consortium to Establish a Registry for Alzheimer’s disease (CERAD) word list recall test also addresses this neurocognitive domain through delayed recall of a learned word list and is faster to apply than the RAVLT. However, the disadvantage of this test is that it is geared toward dementia patients of higher age, and normative data for younger patients are not available . The Free and Cued Selective Reminding Test (FCSRT) is an alternative verbal memory test that, similar to the RAVLT, provides normative data versus younger adults, and might therefore also be suited to cognitive assessments in NP-C .
A number of previous studies in patients with NP-C have described impaired executive functions (e.g. set-shifting and word fluency) and attention as the primary neurocognitive deficit in NP-C [5, 15,16,17, 19]. Our findings are in line with previous published evidence, in that executive functions as measured by the TMT-A/B and word fluency as measured by the RWT, were the most frequently impaired domains in NP-C patients . However, the frequency and magnitude of these impairments were actually lower among NP-C patients on the majority of neurocognitive tests assessing attention and executive functions versus eAD. As a result, these tests cannot be expected to function as differential cognitive markers on their own.
Interestingly, the RWT word fluency (letters) task was the only neurocognitive measure on which NP-C patients were more impaired than eAD patients at the raw score level. However, the NP-C versus eAD effect-size seen with this parameter was small and non-significant, and the frequency of impaired cases (compared with age-matched normative data) on this test was similar in both groups.
While global dementia screening tools such as the MMSE, or more specific tools such as the FAB may not be powerful enough to distinguish specific neurocognitive deficits between NP-C and eAD, the majority of NP-C patients in our study presented with impaired performance on both of these scales. In particular, FAB may prove useful for this purpose in clinical practice as it effectively assesses executive dysfunctions in a time-economic way. Overall, due to lack of specificity and the lack of normative age-matched control data in younger patients, these screening tests cannot substitute an extensive neurocognitive assessment, particularly in addressing memory and executive function.
The small sample size, particularly of the NP-C group is a weakness of this study. However, this is due to the extreme rarity of NP-C and the single-centre nature of this study. The between-group differences in age in the NP-C and eAD patients introduces a further degree of uncertainty, with patient age acting as a potential confounding factor in our statistical analyses. Age has an important influence on the range and severity of cognitive, neurological, visceral and psychiatric symptoms in NP-C [1, 2, 15]. It is notable that patients with eAD in this study were significantly older than those with NP-C. While this could be considered as a study limitation, it should also be noted that, in general, cognitive impairment in NP-C has a lower age at onset compared with eAD. While cognitive deterioration is observed in most patients with adolescent/adult-onset NP-C [1, 2, 15], EOCD is most usually recognized among patients with childhood-onset NP-C in the form of intellectual developmental disorder, poor school performance, and learning disabilities [4, 15, 48]. One difficulty in this respect is that not all neurocognitive tests are similarly applicable in different age-groups, particularly in patients with the juvenile-onset or early adolescent-onset forms: this constitutes a problem. For instance, Klarner et al. used the CERAD battery to determine the cognitive profile of patients with NP-C . However, this test battery is not associated with normative data for patients aged < 50 years and frequently produces ceiling effects in younger patients. In contrast, the RCFT, RAVLT, TMT, RWT and WMS-digit span tests included in the current study all provide normative data for both children, as well as older age groups. The current test battery may therefore be more suited for use in NP-C than classical senile dementia test batteries like the CERAD or dementia screenings.
Finally, structural neuroimaging data to investigate potential links between memory scores and medial temporal lobe atrophy in eAD versus NP-C, and the possible relationship between frontal executive functions and frontal/subcortical atrophy with executive dysfunction, are a subject for potential, future studies. In addition, more specific cognitive and behavioural functions associated with frontal lobe integrity (e.g., social cognition tests, abnormal behaviour) may also function as differential markers for NP-C. However, these aspects have not yet been tested in detail in this rare patient group.
In conclusion, based on our findings, we recommend that general dementia screening assessments (e.g., MMSE, FAB) should not be used in isolation to evaluate cognitive performance in patients with suspected NP-C, as these patients may present with milder cognitive deficits than patients with eAD. Such screening studies may therefore prevent the detection of important differences in the neurocognitive profiles between eAD and NP-C. Detailed, yet easy-to-apply neurocognitive tests such as the RAVLT assessing verbal episodic memory, the TMT-B assessing set-shifting and a verbal letter fluency task, with normative data available for age-groups typically associated with NP-C, appear more appropriate. Further studies in larger numbers of patients are warranted. Parallel studies of such neurocognitive scales alongside imaging parameters (e.g., based on MRI volumetry or DTI) would allow further insight through the assessment of underlying neuroanatomical correlates of cognitive dysfunction in NP-C.
Area under the curve
Diffusion tensor imaging
Early Alzheimer’s disease
Early-onset cognitive decline
Frontal Assessment Battery
Frontal assessment battery
Free and Cued Selective Reminding Test
Mini-mental status examination
Magnetic resonance imaging
Niemann-Pick disease type C
Positron emission tomography
Rey Auditory Verbal Learning Test
Rey Complex Figure Test and Recognition Trial
Receiver operating characteristics
Regensburger verbal fluency test
Trail Making tests A & B
Wechsler Memory Scale
Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.
Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, for the NP-C working group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106:330–44.
Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis. 2013;36:687–702.
Imrie J, Heptinstall L, Knight S, Strong K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol. 2015;15:257.
Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, et al. The adult form of Niemann-Pick disease type C. Brain. 2007;130:120–33.
Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, D’Agostino AN, et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995;89:227–38.
Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Månsson JE, et al. Amyloid-beta metabolism in Niemann-Pick C disease models and patients. Metab Brain Dis. 2012;27:573–85.
Malnar M, Hecimovic S, Mattsson N, Zetterberg H. Bidirectional links between Alzheimer’s disease and Niemann-Pick type C disease. Neurobiol Dis. 2014;72(Pt A):37–47.
Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K, Murayama S. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann Neurol. 2002;52:351–5.
Cupidi C, Frangipane F, Gallo M, Clodomiro A, Colao R, Bernardi L, et al. Role of Niemann-Pick type C disease mutations in dementia. J Alzheimers Dis. 2017;55:1249–59.
Hendriksz CJ, Anheim M, Bauer P, Bonnot O, Chakrapani A, Corvol JC, et al. The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease. Curr Med Res Opin. 2017;33:877–90.
Schicks J, Muller Vom Hagen J, Bauer P, Beck-Wodl S, Biskup S, Krägeloh-Mann I, et al. Niemann-Pick type C is frequent in adult ataxia with cognitive decline and vertical gaze palsy. Neurology. 2013;80:1169–70.
Bauer P, Balding DJ, Klünemann HH, Linden DE, Ory DS, Pineda M, et al. Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study. Hum Mol Genet. 2013;22:4349–56.
Maubert A, Hanon C, Sedel F. Psychiatric disorders in adult form of Niemann-Pick disease type C. L’Encephale. 2016;42:208–13.
Bergeron D, Poulin S, Laforce R Jr. Cognition and anatomy of adult Niemann-Pick disease type C: insights for the Alzheimer field. Cogn Neuropsychol. 2017;35:1–14. https://www.tandfonline.com/doi/full/10.1080/02643294.2017.1340264.
Heitz C, Epelbaum S, Nadjar Y. Cognitive impairment profile in adult patients with Niemann Pick type C disease. Orphanet J Rare Dis. 2017; [accepted October 2017]
Klarner B, Klünemann HH, Lurding R, Aslanidis C, Rupprecht R. Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis. 2007;30:60–7.
Tong F, Koeppen AH, Ramirez-Zamora A, Patterson MC, Zimmerman EA. Adult-onset Niemann-Pick disease type C presenting with ataxia and cognitive decline. Ann Neurol. 2014;76(Suppl 18):S97.
Stampfer M, Theiss S, Amraoui Y, Jiang X, Keller S, Ory DS, et al. Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8:35.
Walterfang M, Fietz M, Fahey M, Sullivan D, Leane P, Lubman DI, et al. The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci. 2006;18:158–70.
Hulette CM, Earl NL, Anthony DC, Crain BJ. Adult onset Niemann-Pick disease type C presenting with dementia and absent organomegaly. Clin Neuropathol. 1992;11:293–7.
Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765–72.
Chien YH, Peng SF, Yang CC, Lee NC, Tsai LK, Huang AC, et al. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis. 2013;36:129–37.
Actelion Pharmaceuticals Ltd. Miglustat (Zavesca) summary of product characteristics [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000435/human_med_001171.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125]. Accessed 23 Jan 2018.
Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017;390:1758–68.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
Pineda M, Perez-Poyato MS, O’Callaghan M, Vilaseca MA, Pocovi M, Domingo R, Ruiz Portal L, Verdu Perez A, Temudo T, Gaspar A, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab. 2010;99:358–66.
Helmstädter C, Lendt M, Lux S. Verbal learning and memory ability test. A practical and differentiated tool for the examination of verbal memory. Schweiz Arch Neurol Psychiatr. 1990;141:21–30.
Meyers J, Meyers K. Rey Complex Figure Test and Recognition Trial: Professional Manual. Odessa: Psychological Assessment Resources; 1995.
Reitan R, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press; 1985.
Aschenbrenner A, Tucha O, Lange K. Regensburger Wortflüssigkeits-Test (RWT). Göttingen: Hogrefe; 2001.
Wechsler D. Wechsler Memory Scale – Revised Edition: Manual. New York: The Psychological Corporation; 1987.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Benke T, Karner E, Delazer M. FAB-D: German version of the frontal assessment battery. J Neurol. 2013;260:2066–72.
Fu R, Yanjanin NM, Elrick MJ, Ware C, Lieberman AP, Porter FD. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am J Med Genet A. 2012;158A:2775–80.
Cologna SM, Cluzeau CV, Yanjanin NM, Blank PS, Dail MK, Siebel S, et al. Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1. J Inherit Metab Dis. 2014;37:83–92.
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
Manganelli F, Dubbioso R, Iodice R, Topa A, Dardis A, Russo CV, et al. Central cholinergic dysfunction in the adult form of Niemann pick disease type C: a further link with Alzheimer’s disease? J Neurol. 2014;261:804–8.
Teipel S, Drzezga A, Grothe MJ, Barthel H, Chetelat G, Schuff N, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14:1037–53.
Walterfang M, Abel LA, Desmond P, Fahey MC, Bowman EA, Velakoulis D. Cerebellar volume correlates with saccadic gain and ataxia in adult Niemann-Pick type C. Mol Genet Metab. 2013;108:85–9.
Bowman EA, Walterfang M, Abel L, Desmond P, Fahey M, Velakoulis D. Longitudinal changes in cerebellar and subcortical volumes in adult-onset Niemann-Pick disease type C patients treated with miglustat. J Neurol. 2015;262:2106–14.
Walterfang M, Patenaude B, Abel LA, Klünemann H, Bowman EA, Fahey MC, et al. Subcortical volumetric reductions in adult Niemann-Pick disease type C: a cross-sectional study. Am J Neuroradiol. 2013;34:1334–40.
Walterfang M, Fahey M, Desmond P, Wood A, Seal ML, Steward C, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology. 2010;75:49–56.
Battisti C, Tarugi P, Dotti MT, De Stefano N, Vattimo A, Chierichetti F, et al. Adult onset Niemann-Pick type C disease: a clinical, neuroimaging and molecular genetic study. Mov Disord. 2003;18:1405–9.
Huang JY, Peng SF, Yang CC, Yen KY, Tzen KY, Yen RF. Neuroimaging findings in a brain with Niemann-Pick type C disease. J Formos Med Assoc. 2011;110:537–42.
Patai EZ, Gadian DG, Cooper JM, Dzieciol AM, Mishkin M, Vargha-Khadem F. Extent of hippocampal atrophy predicts degree of deficit in recall. Proc Natl Acad Sci U S A. 2015;112:12830–3.
Bonner-Jackson A, Mahmoud S, Miller J, Banks SJ. Verbal and non-verbal memory and hippocampal volumes in a memory clinic population. Alzheimers Res Ther. 2015;7:61.
Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.
Matthew Reilly PhD at InTouch Medical Ltd. provided medical writing support in the preparation of this manuscript, paid for by the University Hospital of Münster, Münster, Germany.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All patients included in the study provided written informed consent. The study protocol was approved by the local ethics committee (2012–365-f-S), and was developed in accordance with the 1975 Helsinki declaration, as revised in 2000.
TD has received speaker honoraria, consultancy fees, and travel expenses from Genzyme, Shire, Sanofi Aventis, Novartis, Actelion Pharmaceuticals and Amicus, research support from Genzyme, Shire, Amicus and Actelion Pharmaceuticals, and educational grants from Novartis, Roche and Biogen. AJ received travel expenses from Actelion Pharmaceuticals.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.